135 mg/m2 paclitaxel showed no clear difference in overall survival compared with 175 mg/m2 paclitaxel (low certainty).
It is very uncertain whether weekly paclitaxel changes response rate compared with three‐weekly paclitaxel (very low certainty).
135 mg/m2 paclitaxel showed no clear difference in response rate compared with 175 mg/m2 paclitaxel (low certainty).
The review found no eligible studies for this question.
135 mg/m2 paclitaxel showed no clear difference in progression‐free survival compared with 175 mg/m2 paclitaxel (low certainty).
135 mg/m2 paclitaxel showed no clear difference in neurotoxicity compared with 175 mg/m2 paclitaxel (low certainty).
The review found no eligible studies for this question.
The review found no eligible studies for this question.
It is very uncertain whether weekly paclitaxel changes response rate ‐ platinum‐sensitive compared with three‐weekly paclitaxel (very low certainty).
It is very uncertain whether weekly paclitaxel changes response rate ‐ platinum‐resistant compared with three‐weekly paclitaxel (very low certainty).
The review found no eligible studies for this question.
It is very uncertain whether weekly paclitaxel changes progression‐free survival compared with three‐weekly paclitaxel (very low certainty).
It is very uncertain whether weekly paclitaxel changes neurotoxicity compared with three‐weekly paclitaxel (very low certainty).
Weekly paclitaxel may leads to lower neutropenia compared with three‐weekly paclitaxel (low certainty).
Weekly paclitaxel may leads to lower alopecia compared with three‐weekly paclitaxel (low certainty).